 Shares of Ovid Therapeutics NASDAQ: OVID have more than doubled over the past four months, a performance the clinical-stage biotech company owes in part to a positive rating from an analyst. In March and again in June, Ladenburg Thalmann analyst Michael Higgins gave the stock a 20 price target. The biotech has a handful of potential treatments in its pipeline, the most advanced of which is OV101, which targets Angelman syndrome. 